# Commission Delegated Regulation (EU) 2017/1569 of 23 May 2017 supplementing Regulation (EU) No 536/2014 of the European Parliament and of the Council by specifying principles of and guidelines for good manufacturing practice for investigational medicinal products for human use and arrangements for inspections (Text with EEA relevance), Article 26: Transitional provision

Extent: E+W+S+N.I.

The Member States may continue to apply national transposition measures adopted under Commission Directive 2003/94/EC to the manufacture of investigational medicinal products used in clinical trials governed by Directive 2001/20/EC of the European Parliament and of the Council in accordance with the transitional provisions laid down in Article 98 of Regulation (EU) No 536/2014.

---
Source: https://www.legislation.gov.uk/eur/2017/1569/article/26 (the official version)
Page: https://openlegislation.uk/eu-regulation-2017-1569/article-26
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.